ADNI3 Private Partner Scientific Board Partner Quotes

ADNI3 Private Partner Scientific Board Partner Quotes

Alector, Inc.

At Alector, we are pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, with the goal of stopping neurodegeneration in its tracks. We are proud to partner with the FNIH and ADNI to work collaboratively across the industry on this monumental initiative, to further understand Alzheimer’s disease and work towards the shared goal of earlier diagnosis and better treatment for millions living with this devastating disease.”

Sara Kenkare-Mitra, Ph.D.
President and Head of Research and Development
Alector, Inc.

Alzheimer’s Association

Advancements in Alzheimer’s imaging and fluid biomarkers have enabled physicians and researchers to more accurately diagnose Alzheimer’s disease, select research participants and measure response to investigational therapies. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) has played – and continues to play – an important role in these advancements. The Alzheimer’s Association has supported ADNI since its launch in 2004, and we look forward to the launch of ADNI4, with its focus on validation of Alzheimer’s biomarkers and enhanced recruitment of underrepresented populations. 

The Association appreciates the impact that the ADNI Private Partner Scientific Board (PPSB) has had in its support of this landmark global study. Progress to date in this project is due in significant part to the outstanding leadership of the Foundation of the National Institutes of Health, in partnership with the ADNI core leaders and PPSB scientists, in coordinating and managing the ADNI PPSB and its multiple workgroups.”

Maria C. Carrillo, Ph.D.
Alzheimer’s Association
Chief Science Officer

Alzheimer’s Drug Discovery Foundation

The Alzheimer’s Drug Discovery Foundation is dedicated to accelerating the development of biomarkers for Alzheimer’s and related dementias, which are essential to patients receiving earlier and more reliable diagnosis, as well as tracking their responses to treatment. We are excited to be a part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) as this will make biomarker data more widely accessible and build on our efforts to advance the most promising research.”

Howard Fillit, M.D.
Co-Founder and Chief Science Officer
Alzheimer’s Drug Discovery Foundation

Araclon Biotech, S.L.

At Araclon Biotech, we are committed to the identification and prevention of Alzheimer’s Disease from its earliest stages. We are pioneers in the use of blood-based biomarkers as tools to recognize individuals with incipient underlying pathology. In addition, we are actively working in the development of an active immunotherapy against Aβ (ABvac40, currently at the end of Phase II) with the aim of contributing with an effective treatment to address and prevent AD. Araclon is pleased to be part of the FNIH and ADNI, joining forces with other partners in our common desire to have a meaningful impact in the early and reliable diagnosis for AD patients, along with novel and effective treatments.”       

Jose Terencio, Ph.D.
Chief Executive Officer
Araclon Biotech, S.L.


ADNI data has enabled Biogen to better understand disease progression and enhance patient selection and trial design.”

Samantha Budd Haeberlein, Ph.D.
Senior Vice President, Head Neurodegeneration Development Unit

C2N Diagnostics

We’re proud to be a partner in this vitally important work that seeks to identify the earliest changes in brain structure and function that signal the onset and progression of Alzheimer’s disease. It’s a testament to the quality and rapid pace of innovation in the field that ADNI researchers are now adding blood-based biomarkers to their standard set of prospective screening tools as they collect, validate and use data that will be beneficial to the entire medical community and for patients and families.”

Joel Braunstein, M.D., MBA
Chief Executive Officer
C2N Diagnostics

Cogstate Ltd

Cogstate’s mission to simplify the measurement of cognition and democratize brain health assessment goes hand-in-hand with ADNI’s crucial work developing biomarkers for earlier detection of Alzheimer’s disease (AD). We are honored to provide our rapid and reliable digital cognitive assessments for these innovative studies and work in tandem with other leading organizations to contribute to advances in AD research and help the millions impacted by dementia worldwide.”

Tanya O’Connor
Vice President, Healthcare & Research
Cogstate Ltd

Denali Therapeutics, Inc.

ADNI has been a valuable and trusted partner in our mission to defeat degeneration. There is no better source in the world for understanding the relationship between well-established imaging and biofluid biomarkers of AD like amyloid; more exploratory biomarkers like CSF lipids, and the clinical progression of people with Alzheimer’s disease.”

Kimberly Scearce-Levie, Ph.D.
Vice President, Translational Sciences
Denali Therapeutics, Inc

Eli Lilly and Company

At Lilly, we are committed to removing barriers to ensure that patients have broad access to advanced diagnostics to support timely and accurate Alzheimer’s disease diagnosis. We believe this enables diagnosis in earlier stages of disease and more appropriate treatments. Our robust diagnostic and treatment pipeline reflects innovation, investments and collaborations aimed at the entire spectrum of Alzheimer’s disease. We are excited to continue to partner with the FNIH and other industry leaders on the ADNI project to advance the science that can lead to innovative and accessible diagnostics for patients.”

Mark Mintun, M.D.
Senior Vice President, Neuroscience Research & Development, Eli Lilly and Company
and President, Avid Radiopharmaceuticals


Here at EUROIMMUN we are very proud to be supporting the Foundation for the National Institutes of Health’s work with the Alzheimer’s Disease Neuroimaging Initiative (ADNI3) as a part of our very strong commitment to the diagnosis of neurological and neurodegenerative diseases. ADNI, from it’s very beginning, has been an often-copied beacon of cooperation which has highlighted the industry’s desire to provide quality of life solutions for this devastating condition. I think it is fair to say that ADNI has influenced and advanced the science in AD research and, in particular, study design in so many ways that it is hard to imagine the advancements over the last 10 years in AD without this groundbreaking epidemiological study acting as a platform to build upon.”

Lars Komorowski, Ph.D.
Institute of Experimental Immunology
Affiliated to EUROIMMUN AG

GE Healthcare Inc.

At GE HealthCare, our vision is to deliver on the promise of precision health through the power of advanced imaging diagnostics. ADNI and GE HealthCare share the missions of advancing science to support the validation of biomarkers for Alzheimer’s disease. Ultimately, this enables clinicians to make faster, more informed decisions for patients, leading to the right diagnosis at the right time for the right patient. In turn, this can improve outcomes for patients, providers, health systems and researchers around the world. We are proud to continue to support FNIH and ADNI in their future endeavors.”

Mark Hibberd, M.D., Ph.D.
Chief Medical Officer and Head of Global Medical Services
GE HealthCare


Invicro, part of REALMTM IDx, is a global research partner to pharmaceutical, biotech, and contract research organizations. Invicro helps to enhance the discovery and development of life-changing drugs, using a novel platform that combines best-in-class expertise, imaging biomarkers, core lab services, analytics, and software. A significant part of our business focuses on the delivery of advanced imaging services for Ph II/III clinical trials in Alzheimer’s’ Disease (AD) and thus we greatly value our partnership with ADNI. We regularly use ADNI data for the design and statistical powering of clinical AD trials in conjunction with pharmaceutical partners who are developing novel therapeutics for Alzheimer’s Disease. This data also enables us to refine our analytical algorithms that are used to analyze PET and MR imaging data. Our leading scientists regularly join the ADNI monthly calls to understand the richness of the ADNI data set and ensure that our organization is best placed to serve pharmaceutical companies with the optimal biomarkers and services required for their trials.”

Roger Gunn, Ph.D.
CSO, Neuroscience


At IXICO we are dedicated to supporting clinical trials in neuroscience with imaging CRO services and AI data analytics. Since its inception, the ADNI study has been leading the way in the development of novel PET and MR image acquisition as well as analysis approaches. As ADNI is setting imaging standards for clinical trials in Alzheimer‘s disease and other neurodegenerative diseases, it is a mission-critical initiative in our community’s endeavour to develop treatment in areas of high unmet need. At IXICO we are proud for having been a part of ADNI for several years and we look forward to continued engagement as the initiative is entering its fourth phase.”

Robin Wolz, Ph.D.
Chief Scientific Officer

Janssen Research & Development, LLC

Building on our commitment to the care and treatment of Alzheimer’s disease, we’re proud to support the Foundation for the National Institutes of Health (FNIH) on the Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3), where researchers are working to revolutionize the understanding of pre-symptomatic Alzheimer’s disease. These advancements in neuroimaging demonstrate that we have an enhanced view of the brain, allowing us to push the boundaries on what’s possible – from ensuring earlier diagnosis to enabling the development of more targeted and innovative treatment options that better address the unmet needs of patients.”

Bill Martin, Ph.D.
Global Therapeutic Area Head, Neuroscience
Janssen Research & Development, LLC

National Institutes of Health’s National Institute on Aging

ADNI has changed science, and has changed our understanding of science, in many different ways. ADNI is very important as laying the groundwork for a lot of neuroscience research, studying the brain and studying, in particular, how the brain goes wrong when we get old. So that’s why ADNI was started: to develop methods of studying dementia and, in particular, to develop methods that could be used in randomized clinical trials.”

John Hsaio, M.D.
Research Allocation and Review Committee Representative, 2004 – the present
Program Director, Division of Neuroscience, National Institute on Aging

Roche and Genentech, A Member of the Roche Group

The ADNI data have been critical to how we choose enriched populations, harmonise and optimise study protocols, approach validation of assays and how we think about the implication of biomarkers for disease pathophysiology.”

Gregory Klein
Head Clinical Imaging
Neuroscience and Rare Diseases

Making a meaningful impact in Alzheimer’s Disease requires committing to a journey of discovery that involves collaborating with equally passionate partners. Roche is pleased to be part of ADNI, a public-private partnership that has made major contributions to Alzheimer’s research and promoted our collective progress.”

Rachelle Doody, M.D., Ph.D.
Global Head of Neurodegeneration
Roche and Genentech, A Member of the Roche Group

Saladax Biomedical, Inc.

We have participated in the ADNI PPSB for more than a decade now and have found it to be an excellent collaborative endeavor. There are very few examples in healthcare where representatives from both academia and industry can get together to discuss data, set up strategies and exchange ideas in a very open forum. This has helped to greatly move the field forward in advancing analytical methods and disease modifying agents.”

Salvatore J. Salamone, Ph.D.
President and CEO
Saladax Biomedical, Inc.


In the field of neuroscience, Servier focuses its research on rare neurodegenerative diseases. Servier targets proteinopathies, characterized by abnormal accumulation of certain proteins, such as tauopathies, e.g. Progressive Supranuclear Palsy.

At Servier we are pleased to have participated and contributed to ADNI as a partner. ADNI has had a key role to boost innovation and knowledge in Alzheimer Disease, promoting standardization and validation of imaging and biofluid biomarkers, including blood biomarkers, and establishing pre-competitive open discussions and networks across stakeholders. ADNI will serve as a model to go faster in terms of disease knowledge, biomarker discovery and validation in other rare neurodegenerative diseases, including tauopathies. This will allow the use of key biomarkers to support decision making in future clinical development plans and address new therapeutics for patients benefit.”

Johannes Krupp
Research Program Director Neurology, Neuroscience and Immuno-inflammation Therapeutic Area

Nolwen Guigal-Stephan
Head of Clinical Biomarker Development, Translational Medicine


ADNI has been a pioneering public-private partnership since the early 2000s and its longevity is testament to its continued value and leadership in the science of drug development and research in AD. The PPSB provides a unique forum for participating companies to interact with each other and with ADNI core leadership; we are delighted to continue our participation and support.”

Adam Schwarz, Ph.D.


Leave a comment

Your email address will not be published. Required fields are marked *